Skip to main content
رجوع
CASBF logo

CanSino Biologics Inc.

جودة البيانات: 100%
ذروة بيع
CASBF
OTC Healthcare Drug Manufacturers - Specialty & Generic
KWD 3.86
KWD 0.00 (0.00%)
القيمة السوقية: 1.35B
نطاق اليوم
KWD 3.86 KWD 4.10
نطاق 52 أسبوعًا
KWD 3.20 KWD 6.99
حجم التداول
1,200
متوسط 50 يوم / 200 يوم
KWD 4.29 / KWD 4.91
الإغلاق السابق
KWD 3.86

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E 49.7 0.4
P/B 0.3 2.9
ROE % 0.5 3.7
Net Margin % 2.6 3.8
Rev Growth 5Y % -29.9 10.0
D/E 0.4 0.2

النقاط الرئيسية

Revenue declined -29.86% annually over 5 years
ROE of 0.53% is below average
Debt/Equity of 0.41 — conservative balance sheet
Negative free cash flow of -626.43M
P/E of 49.66 — premium valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 55.98%

النمو

Revenue Growth (5Y)
-29.86%
Revenue (1Y)26.12%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
0.53%
ROIC0.25%
Net Margin2.61%
Op. Margin2.24%

الأمان

Debt / Equity
0.41
Current Ratio2.42
Interest Coverage0.00

التقييم

P/E Ratio
49.66
P/B Ratio0.27
EV/EBITDA77.49
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 26.12% Revenue Growth (3Y) 73.61%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -29.86% Earnings Growth (5Y) -65.49%
Profitability
Revenue (TTM) 1.04B Net Income (TTM) 27.15M
ROE 0.53% ROA 0.34%
Gross Margin 0.00% Operating Margin 2.24%
Net Margin 2.61% Free Cash Flow (TTM) -626.43M
ROIC 0.25% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.41 Current Ratio 2.42
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio 49.66 P/B Ratio 0.27
P/S Ratio 1.30 PEG Ratio -2.89
EV/EBITDA 77.49 Dividend Yield 0.00%
Market Cap 1.35B Enterprise Value 1.81B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.04B 824.88M 345.18M 1.03B 4.30B
Net Income 27.15M -378.88M -1.48B -909.43M 1.91B
EPS (Diluted) 0.11 -1.53 -6.01 -3.69 7.74
Gross Profit 0.0 580.45M -876.02M -186.61M 3.00B
Operating Income 23.30M -403.39M -2.04B -1.37B 1.94B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 7.96B 9.32B 11.47B 11.87B 6.75B
Total Liabilities 3.05B 4.03B 4.22B 3.33B 677.22M
Shareholders' Equity 4.91B 5.27B 6.75B 8.00B 6.07B
Total Debt 2.01B 2.70B 2.70B 1.37B 142.54M
Cash & Equivalents 1.56B 2.05B 3.39B 5.46B 4.45B
Current Assets 4.28B 5.18B 7.73B 9.29B 5.42B
Current Liabilities 1.77B 2.59B 2.94B 2.87B 412.85M